Stability of Ursodiol in SyrSpend SF Cherry Flavored
Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Issue: Nov/Dec 2012 - Volume 16, Number 6
View All Articles in Issue
Page(s): 510-512
Note: Electronic version includes errata or revisions.
Download in electronic PDF format for $75
Abstract: Ursodiol is used in the treatment and prevention of certain types of gallstones and for patients with primary biliary cirrhosis. Ursodiol is marketed for this purpose by Watson Pharma, Inc. as ACTIGALL, by Axcan Scandipharm Inc. as URSO 250 and URSO Forte, and by a number of generic manufacturers. Ursodiol is available as capsules of varying strengths. The need for other dose-form options for those patients who cannot take capsules has led compounding pharmacies to seek other alternatives, namely oral solutions and suspensions. Additionally, some patients are unable to tolerate suspending agents containing alcohol or sorbitol. The objective of this study was to determine the stability of ursodiol in SyrSpend SF Cherry Flavored which does not contain sorbitol or alcohol. The studied sample was compounded into a 30-mcg/mL suspension and stored in a low-actinic plastic bottle at temperatures between 2°C and 8°C. Six samples were assayed at each time point out to 66 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced degradation studies. The sample remained within 90% to 110% of the initial concentration throughout the course of the study. The beyond-use date of this product is at least 66 days, based on data collected when refrigerated and protected from light.
Related Keywords:
Christine M. Geiger, MS, Mark A. Voudrie II, MS, PMP, Bridget Sorenson, BS, CAPM, ursodiol, bile acid, gallstones, cholelithiasis, oral suspension, stability
Related Categories:
EXCIPIENTS, GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Ursodiol in SyrSpend SF Cherry Flavored
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 510-512
|
Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 513-515
|
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Jul/Aug 2013
Pg. 344-346
|
Ursodiol 30 mg/mL in SyrSpend SF Cherry Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 493
|
Stability of Gabapentin in SyrSpend SF
Sorenson Bridget, Voudrie Mark A II, Gehrig Dan
|
Jul/Aug 2012
Pg. 347-349
|
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul
|
Sep/Oct 2015
Pg. 420-427
|
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Voudrie Mark A, Alexander Bridget, Allen D Brett
|
May/Jun 2011
Pg. 255-258
|
Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution)
Voudrie Mark A II, Allen D Brett
|
Jan/Feb 2010
Pg. 82-85
|
Stability of Captopril in SyrSPend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Jul/Aug 2013
Pg. 336-338
|
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
|
Mar/Apr 2012
Pg. 164-166
|
Featured Excipient: Flavor Enhancing Agents
Allen Loyd V Jr
|
Jan/Feb 2003
Pg. 48-50
|
Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Miller Valicia, Morris Tommy C, Graves Richard A
|
Jan/Feb 2019
Pg. 70-76
|
Ursodiol 50-mg/mL Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2011
Pg. 427
|
Stability of Vancomycin in SyrSpend SF
Whaley Paul A, Voudrie Mark A II
|
Mar/Apr 2012
Pg. 167-169
|
Ursodiol 25-mg/mL Oral Liquid
Allen Loyd V Jr
|
Nov/Dec 2005
Pg. 480
|
Stability of Rifampin in SyrSpend SF
Sorenson Bridget, Whaley Paul
|
Mar/Apr 2013
Pg. 162-164
|
Stability of Minoxidil in Espumil Foam Base
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Mar/Apr 2013
Pg. 165-167
|
Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
|
Jan/Feb 2018
Pg. 66-75
|
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
|
Jul/Aug 2020
Pg. 327-336
|
Nifedipine 4.mg/mL in SyrSpend SF pH4 Cherry Flavored
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 327
|
Return to Top |